Healthcare Sys & Biz29 Jul 2026
Medical Training's New Perfectionism: A Silent Epidemic Among Future CliniciansRead article
Healthcare Sys & Biz29 Jul 2026
AI won't replace doctors, but it might erode your core skillsRead articleThe Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Metastatic pancreatic cancer: A new drug could shift your approach
The EMA granted accelerated assessment for an investigational medicine for metastatic pancreatic adenocarcinoma, potentially offering a new option in a difficult disease.
The real reason joint oncology practices need explicit protocols
Running a joint oncology clinic presents unique challenges and benefits, requiring careful navigation of professional boundaries and patient dynamics.
ARHGAP36: A new survival predictor for neuroblastoma patients
High ARHGAP36 levels predict improved 5-year survival in neuroblastoma patients, linking FOXC1-induced expression to altered Hedgehog signaling.
Sitting for Long Stretches Linked to Higher Cancer Mortality Risk
Cancer survival improves. Why are rural outcomes still worsening?
Jideytro offers new hope for ROS1-positive NSCLC after prior therapy
EHR data identifies liver transplant patients at high risk of early graft loss
An EHR-based marker accurately identifies liver transplant recipients at elevated risk of early graft failure and mortality, offering a tool for improved post-transplant management.
Nearly 1 in 10 With Primary Biliary Cholangitis Have CKD
Chronic kidney disease affects 9.5% of patients with primary biliary cholangitis, with hypertension and older age driving incidence.
EHR-derived marker flags liver transplant recipients at high risk of early death
An EHR-based marker identifies liver transplant recipients at increased risk of 90-day mortality, offering a tool for pre-transplant risk stratification and post-operative management.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
Liver Transplant Studies Retracted Over Organ Harvesting Concerns
Why cardiac amyloidosis diagnoses are surging and what it means for GPs
Cardiac amyloidosis diagnoses are increasing due to improved awareness and advanced imaging, revealing a previously underrecognized cause of heart failure.
Pulsed Field Ablation: A New Frontier for Atrial Fibrillation?
Pulsed field ablation offers a novel, non-thermal approach to cardiac tissue destruction, leveraging irreversible electroporation for targeted cell death in arrhythmias.
Heart Failure Treatment in 2026: A Clinical Overview
Heart failure management has changed substantially over the past decade. This clinical overview covers the four pillars of guideline-directed medical therapy, the role of device therapy, and emerging treatments entering practice in 2026.
AI in the ED: Can algorithms truly accelerate acute cardiac care?
Cardiovascular risk: Why men die earlier, women live sicker
How lipid packing dictates caveolae stability at the plasma membrane
Haaland's 6,000-Calorie Diet: Performance Fuel or Health Risk?
Erling Haaland's reported 6,000-calorie daily diet, while fueling elite athletic performance, presents significant long-term health considerations for the general population.
What Is an SGLT2 Inhibitor? Mechanism, Indications, and Evidence
SGLT2 inhibitors block renal glucose reabsorption to lower blood sugar and protect the heart and kidneys. A clinical primer on mechanism, approved agents, key trial evidence, and safety.
The long shadow of head trauma: sport, CTE, and dementia risk
Repeated head impacts in contact sports significantly increase the risk of neurodegenerative diseases, including dementia and chronic traumatic encephalopathy (CTE).
Repeated head impacts: What they mean for dementia risk
Repeated blows to the head in contact sports significantly increase the risk of dementia, particularly in former professional athletes.
Creatine Supplementation: Limited Evidence for Brain Health Benefits
Creatine supplementation shows inconsistent and largely unproven benefits for brain health in healthy adults, with some promise in specific populations facing metabolic stress.
Eptinezumab Improves Cognitive Symptoms in Migraine Patients
Dopamine Agonists: A Fading Role in Parkinson's Treatment?
Roche Halts Huntington's Gene-Silencing Programs
Multiple MyelomaDonor T-cells prevent CMV complications in blood cancer patients
Get the full story6 min readMAHA Monday: The Rush to Publish and Its Clinical Fallout
Get the full story11 min readLiso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment
Get the full story11 min readNew Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
Get the full story7 min readFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
Get the full story8 min readMonoclonal Antibodies May Complicate Transfusion Testing
Get the full story7 min readBlood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections
Get the full story7 min readChemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
Get the full story8 min readPersonalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Get the full story7 min readMacrophages: Dual Role in Haematological Malignancies Explored
Get the full story7 min read
Arthritis Psoriatic
Lung NeoplasmsDrug Resistance MicrobialMolecular Profiling Refines Salivary Gland Tumor Diagnosis
How non-animal models are redefining oncology drug safety
Severe VT in ischaemic cardiomyopathy: Why current care isn't enough
Chronic Migraine: Is the Gut-Brain Axis the Missing Link?
Why lifestyle advice alone still dominates obesity searches
Obesity as Disease: Who Benefits from the Redefinition?
Weight-Loss Jabs May Create a New Kind of Yo-Yo Dieting
Tzield expands its reach: A new option for recently diagnosed pediatric type 1 diabetes
Metabolic Syndrome: Is it accelerating your patients' brain aging?
Online GLP-1 Prescriptions Often Lack Clinical Oversight
· Aug 28 – 31ERS 2026· Barcelona, ES 
· Sep 5 – 9EASD 2026· Milan, IT 
· Sep 28 – Oct 2UEG Week 2026· Vienna, AT 
· Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026· Toronto, CA 
· Oct 21 – 23ESMO 2026· Madrid, ES · Oct 23 – 27AHA 2026· Chicago, US 
· Nov 7 – 9ACR 2026· Washington DC, US · Nov 14 – 19ASH 2026· New Orleans, US · Dec 12 – 15ACC.27 Together With WCC· Houston, US · Apr 10 – 12ESC 2026· Munich, DE · Aug 28 – 31ERS 2026· Barcelona, ES · Sep 5 – 9EASD 2026· Milan, IT · Sep 28 – Oct 2UEG Week 2026· Vienna, AT · Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026· Toronto, CA · Oct 21 – 23ESMO 2026· Madrid, ES · Oct 23 – 27AHA 2026· Chicago, US · Nov 7 – 9ACR 2026· Washington DC, US · Nov 14 – 19ASH 2026· New Orleans, US · Dec 12 – 15ACC.27 Together With WCC· Houston, US · Apr 10 – 12
BostonJun 13 – 16 2026
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.
Desmopressin Dosing Refined for Central Diabetes Insipidus
New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.
Korlym® for Cushing's Syndrome: Patient Experience, Side Effects and 2026 Clinical Data
Patient-reported outcomes from Endo 2026 show Korlym® (mifepristone) cuts weight gain, fatigue and mood disturbances in Cushing's syndrome. Covers mechanism of cortisol receptor blockade, side effect profile, and how it compares to relacorilant.
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Hypercortisolism: Emerging Diagnostic and Management Insights
New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways
GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.
Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.
Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome
Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Afirma Molecular Testing: Unique Situations and New Prognostic Development
Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.
Low Alkaline Phosphatase: Recognizing Clinical Consequences
Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.
Desmopressin Dosing Refined for Central Diabetes Insipidus
New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.
Endocrinologists' Role in Early Thyroid Eye Disease Recognition
Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.
Classic CAH: New Approaches to Glucocorticoid Dosing
Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.
Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives
New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.
XLH Adults: Osteomalacia Persists Despite Conventional Therapy
Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.
Acromegaly Management: Focus on Biochemical Control at ENDO 2026
New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.
Korlym® for Cushing's Syndrome: Patient Experience, Side Effects and 2026 Clinical Data
Patient-reported outcomes from Endo 2026 show Korlym® (mifepristone) cuts weight gain, fatigue and mood disturbances in Cushing's syndrome. Covers mechanism of cortisol receptor blockade, side effect profile, and how it compares to relacorilant.
Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism
A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.
Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome
A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.
Peer Insights on Once-Daily Weight Management Therapy at endo 2026
Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.
Hypothyroidism: Symptom Burden Persists Despite Euthyroidism
Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
Hypercortisolism: Emerging Diagnostic and Management Insights
New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.
Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026
Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.
Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps
Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.
12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis
A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.
